Digital Therapeutics Market to Reach US$ 39.52 Billion by 2033 at 21.6% CAGR - North America Leads with 42% Share | Livongo, Medtronic, Omada Health

The Global Digital Therapeutics Market reached US$ 6.84 billion in 2024 and is expected to reach US$ 39.52 billion by 2033, growing at a CAGR of 21.6% during the forecast period 2025-2033. The market is expanding rapidly as healthcare systems increasingly adopt software-driven, evidence-based interventions for disease prevention, management, and treatment, particularly for chronic and lifestyle-related conditions.

Digital therapeutics leverage software and connected devices to deliver clinically validated therapies through flexible service models, ranging from fully integrated platforms that combine hardware, software, and clinical support to modular Software-as-a-Service solutions. This adaptability supports broad adoption among payers, healthcare providers, and patients. Market momentum is reinforced by continuous innovation and product launches; for example, in April 2025, Teladoc Health introduced its Next Generation Cardiometabolic Health Program aimed at improving population health and slowing the progression of obesity, diabetes, and hypertension, highlighting the growing role of digital therapeutics in transforming chronic disease management and healthcare delivery.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/digital-therapeutics-market?sai-v

The digital therapeutics market is the sector that delivers evidence-based therapeutic interventions through software and digital platforms to prevent, manage, or treat medical conditions.

Key Developments
✅ December 2025: Healthcare providers expanded adoption of prescription digital therapeutics platforms to support chronic disease management, mental health care, and behavioral therapy through evidence-based software interventions.

✅ October 2025: Digital therapeutics companies enhanced platforms with AI-driven personalization, real-time patient monitoring, and adaptive treatment pathways to improve clinical outcomes and adherence.

✅ August 2025: Integration of digital therapeutics with electronic health records (EHRs) and remote patient monitoring systems improved clinician oversight and data-driven decision-making.

✅ June 2025: Growing acceptance of digital therapeutics by payers and employers accelerated deployment of app-based treatments for diabetes, cardiovascular conditions, and substance use disorders.

✅ March 2025: Clinical trials and regulatory submissions increased for software-as-a-medical-device (SaMD) solutions targeting neurological, respiratory, and metabolic disorders.

Mergers & Acquisitions
✅ December 2025: A leading digital health company acquired a digital therapeutics startup to expand its portfolio of regulated, evidence-based treatment solutions.

✅ October 2025: Strategic partnerships were formed between digital therapeutics developers and pharmaceutical companies to combine drug therapies with software-driven patient support programs.

✅ August 2025: Digital therapeutics firms collaborated with healthcare providers to deploy condition-specific digital treatment pathways at scale.

✅ June 2025: Technology companies entered alliances with insurers to support reimbursement and broader adoption of prescription digital therapeutics.

✅ March 2025: Industry participants partnered with academic and research institutions to validate clinical efficacy and strengthen regulatory compliance of digital therapeutics solutions.

Key Players
2Morrow Inc. | Livongo Health, Inc. | Medtronic Plc. | Omada Health, Inc. | Pear Therapeutics, Inc. | Proteus Digital Health, Inc. | ResMed, Inc. (Propeller Health) | Voluntis, Inc. | Welldoc, Inc.

Key Highlights
2Morrow Inc. - Holds a share of 13.6%: Specializes in evidence-based digital behavior change programs for smoking cessation, stress management, and chronic disease prevention.

Livongo Health, Inc. - Holds a share of 15.2%: Leads the market with AI-driven chronic condition management platforms, real-time health insights, and strong employer and payer adoption.

Medtronic Plc. - Holds a share of 14.4%: Leverages connected medical devices and digital therapeutics to support diabetes, cardiac, and chronic disease management at scale.

Omada Health, Inc. - Holds a share of 12.1%: Focuses on virtual care programs for diabetes prevention, weight management, and cardiometabolic health with proven clinical outcomes.

Pear Therapeutics, Inc. - Holds a share of 10.3%: Known for FDA-authorized prescription digital therapeutics targeting substance use disorders and mental health conditions.

Proteus Digital Health, Inc. - Holds a share of 9.2%: Develops ingestible sensors and digital medicine platforms to improve medication adherence and patient monitoring.

ResMed, Inc. (Propeller Health) - Holds a share of 8.5%: Strong presence in respiratory digital health through connected inhalers and data-driven asthma and COPD management solutions.

Voluntis, Inc. - Holds a share of 7.4%: Provides therapeutic companion software supporting oncology and chronic disease patients with personalized treatment guidance.

Welldoc, Inc. - Holds a share of 9.3%: Delivers FDA-cleared digital therapeutics for diabetes and cardiometabolic conditions using AI-powered coaching and clinical decision support.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=digital-therapeutics-market?sai-v
(Purchase 2 or more Reports and get 50% discount)

Market Drivers
- Rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and mental health conditions.

- Growing adoption of mobile health applications and digital healthcare platforms.

- Increasing demand for personalized, data-driven, and remote treatment solutions.

- Expansion of telehealth and virtual care services globally.

- Advancements in AI, machine learning, and behavioral analytics enabling effective digital interventions.

- Supportive regulatory frameworks and growing clinical validation of digital therapeutics.

- Increasing focus on cost-effective healthcare delivery and improved patient outcomes.

Industry Developments
- Launch of prescription-based digital therapeutics for diabetes, mental health, and chronic disease management.

- Expansion of clinical trials to validate the efficacy of digital therapeutic solutions.

- Growing partnerships between digital therapeutics companies and healthcare providers.

- Integration of digital therapeutics with wearable devices and remote patient monitoring systems.

- Development of AI-driven platforms for personalized therapy and treatment adherence.

- Increasing reimbursement coverage for approved digital therapeutic products.

- Rising investment and acquisitions in the digital therapeutics ecosystem.

Regional Insights
North America - 42% share: "Driven by strong digital health adoption, supportive reimbursement policies, and high prevalence of chronic diseases."

Europe - 28% share: "Supported by growing regulatory clarity, increasing telehealth usage, and strong public healthcare systems."

Asia Pacific - 25% share: "Fueled by rapid digitalization, expanding smartphone penetration, and rising demand for remote healthcare solutions."

Latin America - 3% share: "Boosted by improving digital healthcare infrastructure and growing interest in virtual care platforms."

Middle East & Africa - 2% share: "Driven by increasing investments in digital health, telemedicine adoption, and healthcare modernization initiatives."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/digital-therapeutics-market?sai-v

Key Segments

➥ By Product Type
Software: Digital platforms and applications delivering evidence-based interventions, monitoring, analytics, and personalized therapeutic content.

Devices: Connected medical devices and wearables used to track patient data, support therapy delivery, and enhance treatment adherence.

Others: Includes hybrid solutions, accessories, and supporting technologies integrated with digital therapeutic ecosystems.

➥ By Application
Diabetes: Digital therapeutics designed for glucose monitoring, lifestyle management, medication adherence, and patient education.

Obesity: Solutions focused on weight management through behavioral therapy, nutrition guidance, and activity tracking.

Cardiovascular Diseases (CVD): Platforms supporting cardiac monitoring, risk management, and lifestyle modification to improve heart health.

Central Nervous System (CNS) Diseases: Digital interventions addressing neurological and mental health conditions such as depression, anxiety, and neurological disorders.

Respiratory Diseases: Applications supporting disease monitoring, symptom tracking, and treatment adherence for respiratory conditions.

Smoking Cessation: Behavior-change programs designed to help users quit smoking through coaching, monitoring, and motivational support.

Gastrointestinal Disorders (GID): Digital solutions aiding symptom tracking, dietary management, and patient engagement for digestive health.

Others: Includes applications in oncology, musculoskeletal disorders, women's health, and additional therapeutic areas.

➥ By Sales Channel
Business-to-Business (B2B): Solutions marketed to employers, healthcare providers, payers, and pharmaceutical companies for population health management and clinical support.

Business-to-Consumer (B2C): Direct-to-patient and caregiver sales models offering personalized digital therapeutics through apps and connected devices.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.